抗体来源(Source)
Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (3B4) antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with RSV-F0.
亚型(Isotype)
Mouse IgG1 | Kappa
特异性(Specificity)
This product is a specific antibody specifically reacts with RSV-F0.
应用(Application)
ELISA
纯度(Purity)
>95% as determined by SDS-PAGE.
内毒素(Endotoxin)
Less than 1.0 EU per mg by the LAL method.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70 °C for 3 months after reconstitution;
电泳(SDS-PAGE)
Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (3B4) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
活性(Bioactivity)-ELISA
Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (MALS verified) (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (3B4) (Cat. No. RS0-Y161) with a linear range of 0.098-3.125 ng/mL (QC tested).
Protocol
Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified) (Cat. No. RSF-V52H6) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (3B4) (Cat. No. RS0-Y161) with a linear range of 0.144-9.197 ng/mL (Routinely tested).
Protocol
背景(Background)
Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.